Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT02812342
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib ointment — DRUG
    Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.

Study Details

The purpose of the study is to investigate the use of topical tofacitinib to promote hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis.

Key Dates

Start date
Sep 30, 2016
Status verified
Jan 2019
Primary completion
Jul 31, 2018
Completion
Dec 31, 2018

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tofacitinib ointment
    Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.

Primary Outcome Measure

Percent Change in Severity of Alopecia Tool (SALT) Score [ Time Frame: 6 Months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Yale-New Haven HospitalNew HavenConnecticut06510-

Find similar trials in New Haven, CT

By research site
Yale-New Haven Hospital· New Haven, CT

Related Studies